What Is the Half-Life of Trazodone and Why It Matters

Trazodone’s half-life in healthy adults falls in the range of roughly 5 to 13 hours, with most modern pharmacokinetic studies reporting a terminal half-life around 10 to 13 hours after a single oral dose taken with food. That number shapes nearly every practical decision about the drug, from how often you take it and when drowsiness peaks to how long side effects linger after your last pill. But the half-life is not a single fixed value for everyone, and the reasons it shifts from person to person have real consequences worth understanding.

What a Half-Life of 5 to 13 Hours Means in Practice

A drug’s half-life is the time it takes for the concentration in your blood to drop by half. For trazodone, a randomized crossover trial in healthy adults found terminal half-lives of about 13 hours when the drug was taken with food.¹ Older clinical literature has cited shorter figures, in the 3-to-9-hour range, partly because earlier studies sometimes reported the initial distribution phase rather than the full terminal elimination phase.² In practical terms, after you take a dose, trazodone reaches peak blood levels within one to two hours, then tapers over the next half-day or so. After about four to five half-lives, the drug is essentially cleared from your system. For a half-life around 10 to 13 hours, that means trazodone can take two to three days to wash out completely.

This timeframe matters most for the drug’s sedating effect. Trazodone is frequently prescribed at low doses specifically to help with sleep, and its sedation is strongest when blood levels are highest. Because the half-life is long enough to overlap with the morning, some people feel residual grogginess the next day, especially at higher doses. Clinical experience has consistently shown that weighting the dose toward bedtime, rather than splitting it evenly through the day, produces better sleep at night with less daytime drowsiness.²

Why the Half-Life Is Not the Same for Everyone

Several factors widen the range. Age is the biggest one with consistent data behind it. In older adults, the terminal half-life of trazodone is significantly longer than in younger people, and the total drug exposure, measured by the area under the concentration-time curve, is significantly larger.³ The likely reasons are age-related declines in liver metabolism and possibly changes in how the brain responds to the drug. This means an older adult taking the same dose as a younger one will have more trazodone circulating for a longer period, increasing both the therapeutic effects and the risk of side effects like dizziness and excessive sedation. Dose reductions are standard practice for older patients partly because of this pharmacokinetic shift.

Food also changes the drug’s behavior, though not necessarily the elimination half-life itself. Taking trazodone with food increases the total amount absorbed while blunting and delaying the peak blood level. That delayed, lower peak is why many prescribers advise taking the drug with a small snack: you still get the full dose into your system, but the gentler rise can reduce the sudden wave of drowsiness or lightheadedness that some people experience on an empty stomach.

The Active Metabolite That Extends Trazodone’s Reach

Trazodone does not simply disappear when the liver processes it. The drug is broken down primarily by the liver enzyme CYP3A4 into a metabolite called meta-chlorophenylpiperazine, usually abbreviated mCPP.⁴ This is not an inert waste product. mCPP is pharmacologically active, interacting with serotonin receptors in the brain on its own.⁵ It acts mainly as a nonselective serotonin agonist, which means it can influence mood, anxiety, temperature regulation, and appetite even after the parent drug’s levels have started falling.

The practical consequence is that trazodone’s true duration of action is not fully captured by its own half-life alone. mCPP circulates alongside trazodone and can persist after trazodone itself has dropped. In a case where trazodone and mCPP were measured in a breastfeeding mother about seven hours after dosing, both substances were present in comparable proportions in maternal blood, cord blood, and breast milk, confirming that the metabolite tracks closely with the parent drug during the elimination window.⁶ For someone who experiences side effects like nausea, headache, or jitteriness that seem to outlast what the half-life would predict, mCPP’s lingering activity is a plausible explanation.

Drug Interactions That Change How Fast Trazodone Clears

Because CYP3A4 is the main enzyme responsible for metabolizing trazodone, anything that inhibits or accelerates CYP3A4 will change how long trazodone stays in your body. Strong CYP3A4 inhibitors, a category that includes certain antifungal drugs, some HIV medications, and grapefruit juice in large quantities, can slow trazodone’s breakdown and effectively extend its half-life. The result is higher blood levels than expected, amplifying both sedation and the risk of cardiovascular side effects like drops in blood pressure. Conversely, strong CYP3A4 inducers like certain anti-seizure medications and the herbal supplement St. John’s wort can speed up metabolism, potentially making the drug less effective because it clears too quickly.

Trazodone’s FDA labeling includes warnings about these CYP3A4-mediated interactions, and this is one area where the half-life concept becomes directly actionable. If you are prescribed trazodone and start or stop another medication that affects CYP3A4, the effective half-life of trazodone shifts, and your prescriber may need to adjust the dose accordingly.

Genetics and the Surprising Role of CYP2D6

You might expect that genetic variation in the CYP3A4 enzyme would be the main source of person-to-person differences in trazodone metabolism. The picture is more nuanced than that. A scoping review of genetic polymorphisms found that common CYP450 variations, including those in CYP3A4, do not seem to directly change trazodone’s pharmacokinetics or those of its metabolites in a consistent way.⁷ The one genetic variant that did influence trazodone’s behavior was a polymorphism in the ABCB1 gene, which encodes a transporter protein rather than a metabolic enzyme. People with a specific variant (the T/T genotype at position C3435T) showed lower overall drug exposure, a shorter half-life, and faster clearance.⁷

CYP2D6 tells a different story. One pharmacogenetic study found that while CYP2D6 status did not change trazodone’s half-life or peak concentration, people who are poor metabolizers of CYP2D6 had more side effects like headache and tingling sensations. Interestingly, the patients with the most adverse reactions actually had lower trazodone exposure, leading researchers to suspect that a downstream metabolite, rather than trazodone itself, was responsible for the trouble.⁸ This aligns with what we know about mCPP: the active metabolite has its own pharmacological effects, and how quickly or slowly you process it through secondary pathways can matter as much as how you handle trazodone itself.

Extended-Release Versus Immediate-Release Formulations

Trazodone comes in both immediate-release (IR) tablets and an extended-release (once-a-day) formulation. The half-life of the trazodone molecule is the same in both, but the two formulations deliver the drug into the bloodstream very differently. After a single 300-mg dose of the extended-release form, peak blood levels were about 60 percent lower than those from three 100-mg IR doses spaced eight hours apart.⁹ Over a full day, the total drug exposure from the extended-release version was about 20 percent lower after a single dose compared to the divided IR regimen. However, after a week of daily dosing, the total exposure evened out and the two formulations became equivalent in overall drug exposure, though the extended-release form still had a peak level about 43 percent lower.⁹

This distinction matters because peak levels drive many of trazodone’s acute side effects: the sudden drowsiness, the orthostatic dizziness when you stand up too fast. A flatter, lower peak with the same overall exposure means the extended-release version is designed to deliver the antidepressant effect without the dramatic sedation spike. For people using trazodone specifically to treat depression rather than as a sleep aid, the extended-release form can be easier to tolerate during waking hours.

How Dose Shapes Which Receptors Trazodone Occupies

Trazodone’s pharmacology is unusually dose-dependent, and the half-life interacts with this in a way that has direct clinical relevance. At low doses, around 25 to 50 mg, the drug mainly blocks serotonin 5-HT2A receptors and alpha-1 adrenergic receptors, while partially activating serotonin 5-HT1A receptors. These are the actions that produce sedation and mild anxiety relief. A modeling study of brain receptor occupancy confirmed that at these lower doses, trazodone achieves meaningful occupancy only at those high-affinity receptor targets.¹⁰

At the full antidepressant dose of 300 mg daily, trazodone recruits additional pharmacological actions. It begins to block the serotonin transporter (the same target that SSRIs hit), along with histamine H1 receptors and other serotonin receptor subtypes like 5-HT2C and 5-HT7.¹⁰ The half-life matters here because these additional receptor targets require sustained blood levels to stay occupied. With the extended-release formulation, which maintains more consistent levels throughout the day, the drug can keep those secondary receptors engaged. With the immediate-release form taken once at bedtime, levels may drop too low during the day to maintain serotonin transporter blockade. This is one reason why the extended-release version was developed specifically for depression treatment, while the immediate-release tablets at low doses have become a de facto sleep aid.

What Happens in Overdose

In overdose, trazodone’s half-life takes on a more urgent meaning. Because the drug clears relatively slowly, toxic blood levels persist for an extended period. Reported overdose cases describe patients developing dangerously low blood pressure and prolonged QT intervals on ECG, a heart rhythm abnormality that can trigger life-threatening arrhythmias. In one documented case, a patient who overdosed on trazodone developed progressive QT prolongation peaking at 586 milliseconds, well into the danger zone, along with significant hypotension.¹¹ These effects did not resolve quickly because the drug’s sustained half-life meant it continued acting on the cardiovascular system for many hours.

Trazodone overdoses are less commonly fatal than overdoses of older tricyclic antidepressants, but the cardiovascular risks are real and underscore why the half-life is a safety-relevant number. Emergency treatment is primarily supportive, monitoring heart rhythm and blood pressure while waiting for the drug to clear. The multi-hour elimination timeline means patients typically need observation for at least a day.

Trazodone in Breastfeeding

For nursing mothers, the half-life determines how much drug accumulates in breast milk between feedings. Trazodone and its active metabolite mCPP do pass into breast milk, but the concentrations are low relative to what is in the mother’s blood. An early pharmacokinetic study measured the milk-to-plasma ratio of trazodone at about 0.14, meaning milk contained only about 14 percent of the concentration found in blood. The estimated infant exposure, assuming a typical milk intake, was less than 0.005 mg per kilogram of body weight, compared to the mother’s dose of about 0.77 mg per kilogram.¹²

A more recent case report measured actual trazodone and mCPP levels in breast milk collected about seven hours after the mother’s dose and found concentrations of roughly 50 and 3 ng/mL, respectively, substantially lower than the corresponding maternal blood levels.⁶ The same report noted that cord blood levels at delivery were comparable to maternal blood, meaning placental transfer is much more substantial than transfer through milk. For mothers weighing the decision to breastfeed while taking trazodone, the half-life means the drug is continuously present in milk at low levels rather than spiking and disappearing. Timing a feeding to avoid peak drug concentration in milk (roughly one to two hours after dosing) can further reduce the already small infant exposure, though the overall amounts are small enough that most lactation references consider trazodone relatively low-risk.

Trazodone in Veterinary Medicine

Trazodone has become widely used in veterinary practice, particularly for managing anxiety and situational stress in dogs. The pharmacokinetics differ somewhat across species, which is a useful reminder that half-life is not a universal property of the molecule but depends on the organism processing it. In dogs given a single rectal dose of trazodone, the measured elimination half-life was about 12 hours, broadly similar to what is seen in humans under fed conditions, though the time to peak concentration was dramatically faster at about 15 minutes via that route.¹³ The volume of distribution in dogs was notably large, suggesting the drug spreads extensively into tissues. Veterinarians use this information to time doses before anxiety-provoking events like veterinary visits or thunderstorms, much as physicians use it to time bedtime dosing in people.

1
PubMed Central. Pharmacokinetics of single oral dose trazodone: a randomized, two-period, cross-over trial in healthy, adult, human volunteers under fed condition
2
PubMed. Trazodone dosing regimen: experience with single daily administration
3
PubMed Central. Pharmacokinetic and pharmacodynamic characteristics of trazodone in the elderly
4
PubMed. Metabolism of m-CPP, trazodone, nefazodone, and etoperidone: clinical and forensic aspects
5
PubMed. 1-m-Chlorophenylpiperazine is an active metabolite common to the psychotropic drugs trazodone, etoperidone and mepiprazole
6
PubMed Central. Trazodone Levels in Maternal Serum, Cord Blood, Breast Milk, and Neonatal Serum
7
Therapeutic Drug Monitoring. Influence of Genetic Polymorphisms on the Pharmacokinetics of Trazodone Hydrochloride: A Scoping Review and Future Perspective
8
PubMed Central. CYP2D6 Phenotype as a Predictor of Adverse Drug Reactions in Patients Treated With Trazodone: An Explorative Pharmacogenetic Study
9
PubMed. Safety, tolerability, and pharmacokinetics of once-daily trazodone extended-release caplets in healthy subjects
10
PubMed Central. Estimation of brain receptor occupancy for trazodone immediate release and once a day formulations
11
PubMed Central. Trazodone Overdose Manifesting as Hypotension and QT Prolongation
12
PubMed Central. Excretion of trazodone in breast milk
13
PubMed Central. Pharmacokinetics and efficacy of trazodone following rectal administration of a single dose to healthy dogs